STOCK2S-26016
Based on 1 Customer Validation
STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with IC50s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research.
For research use only. We do not sell to patients.
- Purity: 98.93%
- CAS No.: 332922-63-1
- Formula: C20H19N3O2
- Molecular Weight:333.38
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
IC50: 16 μM (WNK4); 34.4 μM (WNK1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
4.2 μM
Compound: 1
|
Cytotoxicity against HEK293T cells after 40 hrs by CCK8 assay
Cytotoxicity against HEK293T cells after 40 hrs by CCK8 assay
|
[PMID: 28566208] |
| Huh-7 | CC50 |
37.87 μM
Compound: GNF-Pf-3043
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
STOCK2S-26016 (10 and 30 minutes) blocks the effect of L-NAME on phosphorylated sodium-chloride cotransporter (NCC) in mDCT cells[2].
STOCK2S-26016 (25-200 μM) drastically and dose-dependently reduces the phosphorylation of STE20/SPS1-related proline/alanine-rich protein kinase (SPAK) and NCC in mpkDCT cells[1].
STOCK2S-26016 (50-200 μM) drastically and dose-dependently reduces the phosphorylation of SPAK and Na/K/Cl cotransporter 1 (NKCC1) in MOVAS cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 332922-63-1
-
Appearance Solid
-
Molecular Weight 333.38
-
Formula C20H19N3O2
-
Color Light yellow to yellow
-
SMILES
NC1=C(C=CC(NCC2=CC=CO2)=C3)C3=NC4=CC=C(OCC)C=C41
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : ≥ 50 mg/mL (149.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.75 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.75 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Takayasu M, et, al. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy. Biochem J. 2013 Nov 1; 455(3): 339-45. [Content Brief]
[2]. Conghui W, et, al. Low dose L-NAME induces salt sensitivity associated with sustained increased blood volume and sodium-chloride cotransporter activity in rodents. Kidney Int. 2020 Jun 24; S0085-2538(20)30703-1. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | 74.9895 mL |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | 14.9979 mL | |
| 10 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL | 7.4990 mL | |
| 15 mM | 0.2000 mL | 0.9999 mL | 1.9997 mL | 4.9993 mL | |
| 20 mM | 0.1500 mL | 0.7499 mL | 1.4998 mL | 3.7495 mL | |
| 25 mM | 0.1200 mL | 0.5999 mL | 1.1998 mL | 2.9996 mL | |
| 30 mM | 0.1000 mL | 0.4999 mL | 0.9999 mL | 2.4997 mL | |
| 40 mM | 0.0750 mL | 0.3749 mL | 0.7499 mL | 1.8747 mL | |
| 50 mM | 0.0600 mL | 0.3000 mL | 0.5999 mL | 1.4998 mL | |
| 60 mM | 0.0500 mL | 0.2500 mL | 0.4999 mL | 1.2498 mL | |
| 80 mM | 0.0375 mL | 0.1875 mL | 0.3749 mL | 0.9374 mL | |
| 100 mM | 0.0300 mL | 0.1500 mL | 0.3000 mL | 0.7499 mL |